Macrogenics (MGNX) is trading -6% lower at $3.995 today. So far the Health Care sector has been having a mildly positive day, and the share price of the company is floundering behind it's peers.

Some recent news:
1. MacroGenics Inc is reducing its workforce by 15%.
2. The company is closing down an R&D facility.
3. Lemzoparlimab is on track for positive data readouts.

Macrogenics has been trading between a 52-week high of $28.09 and a 52-week low of $2.13. The stock has a market cap of $246 Million.

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

Small Cap Stock MacroGenics Inc. (MGNX) Is A Buy – Analysts
Marketing Sentinel 08-10-22

MacroGenics Jumps Biotech Layoff Bandwagon, Cuts 15% Of Workforce
Benzinga 08-09-22

MacroGenics (MGNX) Q2 2022 Earnings Call Transcript
The Motley Fool 08-09-22

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2022 Results Earnings Call Transcript
Seeking Alpha 08-08-22

Macrogenics: Q2 Earnings Insights
Benzinga 08-08-22